Biofrontera AGBIFRF 58 PB Ratio is 6.97 as of Jul. 04, 2026, which is 15% above its 10-year median of 6.07. GuruFocus rates BIFRF with a GF Score™ of 58/100 and a GF Value™ of $31.34. The stock has 4 warning signs investors should review. Among 921 Drug Manufacturers companies, Biofrontera AG ranks better than 81.65% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-04), Biofrontera AG's share price is $22.68. Biofrontera AG's Book Value per Share for the quarter that ended in Mar. 2026 was $3.25. Hence, Biofrontera AG's PB Ratio of today is 6.97.
Good Sign:
Biofrontera AG stock PB Ratio (=0.83) is close to 1-year low of 0.83.
The historical rank and industry rank for Biofrontera AG's PB Ratio or its related term are showing as below:
BIFRF'
s PB Ratio Range Over the Past 10 Years
Min: 0.47 Med: 6.07 Max: 90.2
Current: 0.83
During the past 13 years, Biofrontera AG's highest PB Ratio was 90.20. The lowest was 0.47. And the median was 6.07.
BIFRF's PB Ratio is ranked better than 81.65% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs BIFRF: 0.83
During the past 12 months, Biofrontera AG's average Book Value Per Share Growth Rate was -12.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -28.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -17.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Biofrontera AG was 90.50% per year. The lowest was -46.60% per year. And the median was 22.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Biofrontera AG PB Ratio Related Terms
Biofrontera AG PB Ratio Historical Data
* Premium members only.
The historical data trend for Biofrontera AG's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera AG PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where Biofrontera AG's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Biofrontera AG's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Biofrontera AG (BIFRF) has a PB Ratio of 6.97 as of Jul. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Biofrontera AG and its competitors. This is 15% above median its historical median of 6.07. Over the past decade, Biofrontera AG's PB Ratio has ranged from 0.47 to 90.20. According to the industry distribution chart, Biofrontera AG ranks #169 out of 921 companies in the Drug Manufacturers industry, placing it in the top 18.3%.
Is Biofrontera AG's PB Ratio too high?
Biofrontera AG's current PB Ratio of 6.97 is 15% above median its 10-year median of 6.07. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 90.20. The Drug Manufacturers industry median PB Ratio is 1.91. Biofrontera AG's value of 6.97 is 264.9% above this industry median. Based on the distribution chart, Biofrontera AG ranks #169 out of 921 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biofrontera AG has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofrontera AG ranks #169 out of 921 companies for PB Ratio. This places Biofrontera AG in the top 18% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.91. Biofrontera AG's value of 6.97 is 264.9% above this benchmark. Historically, Biofrontera AG's own PB Ratio has ranged from 0.47 to 90.20 over the past decade. While the company's 10-year median is 6.07 vs. the industry median of 1.91, Biofrontera AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofrontera AG's current PB Ratio of 6.97 is 264.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Biofrontera AG and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofrontera AG's current PB Ratio is 6.97, which is 15% above median its own 10-year median of 6.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Biofrontera AG (BIFRF) has a current PB Ratio of 6.97. The stock's GF Value™ is $31.34, compared to a current price of $22.68 — trading 27.6% below its estimated fair value. The current PB Ratio is 6.97, which is 15% above median its 10-year median of 6.07 and 264.9% above the Drug Manufacturers industry median of 1.91. Biofrontera AG's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Biofrontera AG (BIFRF), the current PB Ratio is 6.97 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofrontera AG (BIFRF) Overvalued in 2026?
Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued.
The current stock price of $22.68 is trading 27.6% below its estimated GF Value™ of $31.34.
Key valuation signals for BIFRF:
PB Ratio: 6.97 (15% above median its 10-year median of 6.07)
GF Value™: $31.34 vs. price of $22.68 (27.6% below fair value)
Industry Position: 264.9% above the Drug Manufacturers median (#169 of 921)
No single metric tells the full story. See the BIFRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
58GF Score
Get the complete analysis for BIFRF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIFRF has been successfully added to your 
